US · IKT
Inhibikase Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Atlanta, GA 30339
- Website
- inhibikase.com
Price · as of 2024-12-31
$1.91
Market cap 145.56M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $33.51 | +1,654.45% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $0.00 | $202.72 | |||
| 2020 | $38.22 | $90.80 | $4.89 | $0.00 | $47.65 |
| 2021 | $8.28 | $369.56 | $2,536.23 | $0.00 | $0.00 |
| 2022 | $3.98 | $17.70 | $0.44 | $0.00 | $359.61 |
| 2023 | $2.47 | $26.84 | $0.69 | $0.00 | $0.00 |
| 2024 | $1.96 | $33.51 |
AI valuation
Our deep-learning model estimates Inhibikase Therapeutics, Inc.'s (IKT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $33.51
- Current price
- $1.91
- AI upside
- +1,654.45%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IKT | Inhibikase Therapeutics, … | $1.91 | 145.56M | +1,654% | — | — | — | -4.94 | 1.43 | — | -1.40 | — | 1.43 | 0.00% | — | — | -52.00% | 1355.30% | -48.66% | 0.00 | — | 26.37 | 26.13 | 2.05 | -6751.00% | -10000.00% | 579.00% | -14.08% | -5.13 | 907.74% | 0.00% | 0.00% | 35.19% | -1.35 | -2.01 | — | 20.70 |
| AGEN | Agenus Inc. | $3.33 | 113.25M | +151% | -72% | — | +7,590% | -0.22 | -0.15 | 0.49 | -1.04 | — | -0.14 | -50.79% | -116.44% | -219.61% | 95.45% | 58.03% | -86.00% | -0.29 | -1.02 | 0.21 | 0.18 | -0.54 | -2298.00% | -3381.00% | -3214.00% | -314.88% | -0.72 | 76.54% | 0.00% | 0.00% | 0.00% | -0.87 | -0.66 | 1.01 | -15.68 |
| ATOS | Atossa Therapeutics, Inc. | $4.43 | 38.15M | — | — | — | — | -3.65 | 1.30 | — | -0.80 | — | 1.30 | 0.00% | — | — | -31.39% | -1873.25% | -29.54% | 0.00 | — | 14.99 | 14.31 | 2.58 | -1667.00% | — | 45.00% | -22.60% | -4.23 | -1427.53% | 0.00% | 0.00% | 0.00% | -0.80 | -1.05 | — | 7.27 |
| CGTX | Cognition Therapeutics, I… | $1.09 | 80.2M | — | — | — | — | -0.50 | 0.91 | — | 0.21 | — | 0.91 | 0.00% | — | — | -157.19% | 1117.89% | -103.89% | 0.04 | -2158.64 | 2.65 | 2.49 | 0.72 | -116.00% | — | 7617.00% | -167.08% | -2.56 | 589.91% | 0.00% | 0.00% | 0.00% | 0.13 | 0.25 | — | -12.38 |
| ENTX | Entera Bio Ltd. | $1.39 | 63.74M | — | -45% | — | — | -7.46 | 8.81 | 393.14 | -6.58 | — | 8.81 | 4.97% | -5295.58% | -5271.27% | -103.34% | 3479.13% | -90.20% | 0.03 | — | 7.63 | 7.47 | 0.88 | -1935.00% | — | -691.00% | -9.59% | -5.80 | 2475.86% | 0.00% | 0.00% | 0.00% | -6.55 | -9.20 | 346.80 | 13.25 |
| ESLA | Estrella Immunopharma, In… | $1.22 | 51.28M | — | — | — | — | -4.10 | 252.14 | — | -3.99 | — | 252.14 | 0.00% | — | — | — | — | — | 0.00 | — | 0.55 | 0.31 | 0.10 | — | — | — | -21.08% | -2.55 | — | 0.00% | 0.00% | 1.57% | -3.99 | -4.62 | — | -13.22 |
| EXOZ | eXoZymes, Inc. | $8.85 | 74.23M | — | — | — | — | -20.08 | 11.29 | — | -19.55 | -10.68 | 11.29 | 0.00% | — | — | -116.80% | -365.14% | -70.65% | 0.13 | — | 8.12 | 7.84 | 1.49 | 18800.00% | — | 50576.00% | -7.56% | -6.38 | -547.95% | 0.00% | 0.00% | 8.39% | -18.43 | -12.28 | — | 25.10 |
| GLSI | Greenwich LifeSciences, I… | $27.72 | 384.05M | — | — | — | — | -9.97 | 62.14 | — | -9.72 | -13.23 | 62.19 | 0.00% | — | — | -341.95% | 1733.85% | -284.78% | 0.00 | — | 2.62 | 2.62 | 0.26 | 7536.00% | — | 1216.00% | -4.61% | -4.66 | 786.86% | 0.00% | 0.00% | 0.00% | -9.58 | -21.11 | — | 25.79 |
| SRZN | Surrozen, Inc. | $27.80 | 238.29M | — | -83% | — | — | -0.55 | -1.64 | 3.28 | -0.37 | -34.54 | -1.64 | 100.00% | -239.69% | -596.56% | -767.91% | 121.02% | -134.46% | -0.40 | — | 5.32 | 5.07 | 1.08 | 159.00% | — | -5669.00% | -50.45% | -2.41 | 83.66% | 0.00% | 0.00% | 0.00% | -0.35 | -0.50 | 0.84 | -8.68 |
| TTRX | Turn Therapeutics Inc. | $3.60 | 106M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 3858.47% | 179.80% | -87.06% | -0.68 | — | 1.55 | 1.23 | 0.43 | — | — | 273.00% | — | -1.92 | 146.15% | — | 0.00% | — | — | — | — | — |
| TVGN | Tevogen Bio Holdings Inc. | $0.26 | 53.24M | — | — | — | — | -12.18 | -25.05 | — | -12.85 | -0.05 | -25.05 | 0.00% | — | — | 27.16% | 2087.12% | -306.17% | -0.43 | -291.05 | 0.26 | 0.16 | -0.12 | 2330000.00% | — | 4449.00% | -7.18% | -1.33 | 467.53% | 0.00% | 0.00% | 55.48% | -3.15 | -14.07 | — | -89.34 |
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
- CEO
- Mark T. Iwicki
- Employees
- 15
- Beta
- 0.84
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.91) − 1 = — (DCF, example).